静脉输注曲拉西利血管安全方法的探讨

Exploration on the safety method of intravenous infusion of trilaciclib

目的探讨静脉输注曲拉西利的血管安全方法。方法对2023年4月至2024年2月26例静脉输注曲拉西利的小细胞肺癌患者实施血管保护方法,包括用药前血管评估、血管选择、健康教育、局部预防用药,用药中输注部位密切观察、对症处理、用药后健康教育和跟踪随访。观察患者输注曲拉西利后静脉炎的发生情况。结果26例患者中,8例经输液港输注曲拉西利,无静脉炎发生。18例患者经外周静脉留置针输注曲拉西利,其中5例患者出现静脉炎,4例表现为局部硬结形成、按压轻度疼痛,1例表现为局部红肿。均予局部持续外用多磺酸粘多糖乳膏后,患者疼痛减轻,红肿逐渐缓解,硬结范围逐渐缩小。其余患者注射部位无异常表现。结论通过全程对输注曲拉西利的血管实施预防静脉炎保护方法,可以降低静脉炎的严重程度,减少患者的痛苦,保证化疗方案的正常进行。

Objective To explore the safety method of intravenous trilaciclib infusion.Methods A safety protocol of intravenous infusion of trilaciclib was applied on 26 patients with small cell lung cancer from April 2023 to February 2024.The protocol included vascular assessment,vascular selection,health education,sectional preventive medication,infusion site observation,symptomatic treatment,health education and post-infusion follow-up.Phlebitis occured after the infusion of trilaciclib was monitored.Results Among the 26 patients,8 patients infused through the infusion port without phlebitis.For 18 patients received peripheral intravenous infusions,5 of them developed phlebitis.One patient appeared sectional redness and swelling,and 4 patients manifested as sectional induration formation and mild pain when pressing.The continuous use of mucopolysaccharide polysulfate reduced the redness,swelling and the scope of induration,as well as relieved the pain of the patients.Conclusion Implement the safety protocol throughout the infusion of trilaciclib may reduce the incidence and severity of phlebitis,thus relieving the pain of patients,and ensuring the smooth progress of the chemotherapy plan.